健帆生物：9月12日召开董事会会议

Group 1 - The core point of the article is that Jianfan Biological announced the results of its board meeting and discussed the proposal not to adjust the conversion price of its convertible bonds [1] - For the fiscal year 2024, Jianfan Biological's revenue composition is heavily weighted towards the medical device manufacturing sector, which accounts for 99.71% of total revenue, while other sectors contribute only 0.29% [1] - As of the report date, Jianfan Biological has a market capitalization of 19 billion yuan [1]